SANOFI

June 8, 2012

Tor Holtan
Chief Executive
Myasthenia Gravis Foundation of America, Inc.
355 Lexington Avenue, 15th Floor
New York, NY 10017

**Subject:** Discontinuation of Mytelase® (ambenonium chloride) Caplets production

Dear Mr. Holtan,

Because of your very important role in serving patients with myasthenia gravis (MG), we would like to inform you that Sanofi U.S. (a.k.a. sanofi-aventis U.S. LLC) has discontinued producing and manufacturing Mytelase®, which is used for the treatment of patients with MG. This decision has been made solely on the basis of usage and we have informed FDA of this decision. The last manufactured lot of Mytelase® will expire on March 31, 2013. Although we believe supply will be abundant through the fall, actual usage will determine the rate of consumption of product in current stockpiles.

As you know, Mytelase® is an older acetyl cholinesterase inhibitor that has successfully treated MG patients for years. We believe that the newer and alternative treatments available today, both medical and surgical, are effective and allow many people with MG to lead full lives with fewer symptoms.

We respect and admire MGFA's service to people affected by MG and wanted to ensure that you learned of this decision from us directly. If you have any questions or request additional information, please contact us.

Please contact us if you have any questions.

Sincerely,

Gregory P. Geba MD MPH
VP USMA and Deputy CMO
Sanofi U.S.
908-981-5760